Abstract
As new psychoactive substances (NPS) flood the market and “designer drug” sales are on the rise, we are faced with significant – and growing – social and analytical challenges. Here, I offer an overview of a quietly unraveling crisis.
| Original language | English |
|---|---|
| Pages (from-to) | 34-40 |
| Journal | The Analytical Scientist |
| Issue number | 17 |
| Publication status | Published - Feb 2016 |